Physician profile
Kyle Maclean
NPI 1053706184
$2,076.47
in general payments reported to CMS, 2019-2025
13 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $155 · 2021: $173 · 2022: $220 · 2023: $258 · 2024: $420 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.99 |
| Education | $105.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $709.42 | 2021-2025 | Visumax, Veracity Surgical |
| Alcon Vision LLC | $477.72 | 2019-2025 | Clareon, Argos, Lensx |
| Johnson & Johnson Surgical Vision, INC. | $226.87 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Catalys System |
| Glaukos Corporation | $145.22 | 2020-2022 | |
| Allergan, INC. | $131.55 | 2019 | |
| Oyster Point Pharma, INC. | $120.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.93 | 2020-2022 | |
| Rxsight INC | $78.58 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Abbvie INC. | $24.10 | 2022 | |
| Carl Zeiss Meditec, INC. | $21.97 | 2020 | |
| Biotissue Holdings INC. | $20.76 | 2025 | |
| Bausch & Lomb Americas INC. | $17.68 | 2025 | Envista Envy Iol |
| Tarsus Pharmaceuticals, INC. | $13.29 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Maclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.